Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | CCR1 | P32246 | 3/20 | 0.56 |
| ▸ | CCR5 | P51681 | 3/20 | 0.56 |
| ▸ | CCR8 | P51685 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | METAP1 | P53582 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.56 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | TP53 | P04637 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9957568 | 0.96 | KDM4E (0.52) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL9958087 | 0.85 | CYP2A6 (0.46) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL9957930 | 0.84 | KDM4E (0.48) | KDM4ELMNACCR1CCR5CCR8 | |
| Water SCHEMBL9730730 | 0.83 | KDM4E (0.65) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL30989133 | 0.83 | KDM4E (0.72) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL30989132 | 0.83 | KDM4E (0.72) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL1566968 | 0.83 | KDM4E (0.72) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL23203230 | 0.82 | TP53 (0.67) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL1832783 | 0.81 | CCR1 (0.55) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL35754 | 0.80 | KDM4E (0.68) | KDM4ELMNACCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1447 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4392032-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR FOR THE TREATMENT OR PREVENTION OF RENAL CYSTIC DISEASE AND CARDIORENAL SYNDROME | Arena Pharmaceuticals, Inc. (US) | 2024-07-03 | — | — | EP | claimed |
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2024-05-21 | — | — | US | claimed |
| US-11958871-B2 | Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2024-04-16 | — | — | US | claimed |
| CN-111757883-B | Novel inhibitors of bacterial glutaminyl cyclase for the treatment of periodontal disease and related diseases | 弗劳恩霍夫应用研究促进协会 | 2024-02-13 | — | — | CN | claimed |
| CN-115746316-B | Zinc fluorescent metal organic framework material with high recognition performance on aluminum ions and preparation method thereof | 盐城师范学院 | 2023-07-11 | — | — | CN | claimed |
| CN-114437087-B | N-containing organic compound and application thereof in organic light-emitting device and panel | 武汉天马微电子有限公司 | 2023-06-30 | — | — | CN | claimed |
| EP-3720858-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-06-07 | — | — | EP | claimed |
| CN-116113255-A | Organic electroluminescent device, preparation method thereof and panel | 湖北长江新型显示产业创新中心有限公司 | 2023-05-12 | — | — | CN | claimed |
| CN-115746316-A | Zinc fluorescent metal organic framework material with high aluminum ion recognition performance and preparation method thereof | 盐城师范学院 | 2023-03-07 | — | — | CN | claimed |
| WO-2023026185-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR FOR THE TREATMENT OR PREVENTION OF RENAL CYSTIC DISEASE AND CARDIORENAL SYNDROME | ARENA PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | WO | claimed |
| WO-1997046514-A1 | PROCESS FOR THE PREPARATION OF HYDRAZINE DERIVATIVES USEFUL AS INTERMEDIATES FOR THE PREPARATION OF PEPTIDE ANALOGUES | NOVARTIS AG (CH) | 1997-12-11 | — | — | WO | claimed |
| WO-1997040029-A1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | NOVARTIS AG (CH) | 1997-10-30 | — | — | WO | claimed |
| EP-0793643-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-09-10 | — | — | EP | claimed |
| JP-H09502702-A | — | — | 1997-03-18 | — | — | JP | claimed |
| EP-0728145-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | Ciba-Geigy Japan Limited (JP) | 1996-08-28 | — | — | EP | claimed |
| WO-1996016027-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-05-30 | — | — | WO | claimed |
| EP-0706514-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1996-04-17 | — | — | EP | claimed |
| WO-1995012611-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | JAPAT LTD. (CH) | 1995-05-11 | — | — | WO | claimed |
| WO-1995006034-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1995-03-02 | — | — | WO | claimed |
| EP-0604800-A1 | 4- 4- 4-(carboxyalkyl)-phenyl amino carbonyl -phenyl -piperedines as aggregation inhibitors | Dr. Karl Thomae GmbH (DE) | 1994-07-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958871-B2 | Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases | GMPS, GLS, QPCT | KDM4E 2092/4885LMNA 1453/4885CCR1 4653/4885 |
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ADRB3, ADRB1, ADRB2 | KDM4E 4728/4885LMNA 1377/4885CCR1 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.